利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN104758294A 用于COPD、哮喘治疗的吸入药物组合物及其制备方法 无效 - 驳回

用于COPD、哮喘治疗的吸入药物组合物及其制备方法
摘要：
本发明提供一种用于治疗慢性阻塞性肺病(COPD)、支气管哮喘的药物组合物及其制备方法，该药物组合物含有活性成分和药学上可接受的载体，其中所述活性成分包括富马酸福莫特罗二水合物、布地奈德、和噻托溴铵一水合物，三者在药物组合物中的重量百分比依次分别为0.001％-0.4％、0.02％-4％、0.005％-0.8％。本发明提供药物组合物的干粉形式，供患者吸入治疗，干粉吸入剂的特点明显优于喷雾剂和气雾剂，其携带方便，易于操作。干粉形式的药物在室温下具有更好的稳定性，不易受微生物的污染，而且其最显著的进步是靠患者的自主呼吸使药物粉末同步进入呼吸道，可达到肺部定位给药的目的，不存在给药协同配合困难。
摘要（英）：

The invention provides a pharmaceutical composition used for treating COPD and bronchial asthma, and a preparation method thereof. The pharmaceutical composition comprises active ingredients and a pharmaceutically-acceptable carrier, wherein the active ingredients comprise formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate, the weight percentages of formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate in the pharmaceutical composition are 0.001%-0.4%, 0.02%-4% and 0.005%-0.8%, respectively. The pharmaceutical composition provided by the invention is in a dry powder form and is used for inhalation treatment of patients, and the dry powder inhalant has obviously better characteristics compared with sprays and aerosols, and is convenient to carry and easy to operate; medicines in the dry powder form have better stability at room temperature and less susceptibility to microbial contamination; and the most significant progress of the pharmaceutical composition lies in synchronous entering of the medicine powder into a respiratory tract with spontaneous breathing of a patient, so the purpose of specific medicine delivery to the lung is achieved, and difficult coordination and cooperation in the medicine delivery do not exist.

0/0